Biomarkers of Metabolic Syndrome in Clinical Trials This will discuss the latest developments in biomarkers for metabolic syndrome. The topics will include: 1) Pre-analytical and analytical concerns regarding gut and incretin hormones, 2) dysfunctional HDL biomarkers in metabolic syndrome, and 3) kidney injury markers and their usefulness in diabetic nephropathy.
Procalcitonin (PCT) Webinar - How to Incorporate Procalcitonin (PCT) into your Facility's Sepsis Initiative In this webinar Kirsten R. Pyle-Springer, Sepsis Coordinator at Surgical/Neuro/Trauma Intensive Care Unit, Mission Hospital in Mission Viejo, California discusses the Awareness of Sepsis and the risk of Sepsis in critical care settings.
Personalized Stem Cell Therapies for Tissue Regeneration Sheldon Schaffer, Vice President, Aastrom Biosciences, Speaking at Stem Cells World Congress 2010.
Double Knockdown of Transcription Factors DP1 and DP2 Revealed Their Unique Roles in the Regulation of Matrix Metalloproteinase as Well as Cell Cycle Progression Kenichi Yoshida, Associate Professor, Meiji University, speaking at European Biomarkers Summit 2009
Cancer Biomarkers for Diagnosis and Therapy Prediction Ralph Schiess, ETH, Researcher, speaking at Cancer Proteomics 2010.
Blood-Based Exopeptidase Activities as Biomarkers for Cancer Paul Tempst, Memorial Sloan-Kettering Cancer Center, Professor, speaking at Cancer Proteomics 2010.
Domain Antibody-Based Arrays for Breast Cancer Diagnostic Klervi Even, Inserm, speaking at Cancer Proteomics 2010.
Clinical Proteomics – Ready for Prime Time in Urological Cancer Diagnostics? Eric Schiffer, Mosaiques Diagnostics, Clinical Project Manager, speaking at Cancer Proteomics 2010.
Application of Profiling the Antibody Repertoire for Discovery of Cancer Biomarkers. Delores Cahill, University College Dublin, Professor, speaking at Cancer Proteomics 2010.